Latest DEI News

A listing of recent publications by Yale Cancer Center researchers and clinicians in the first quarter of 2024

“We believe future trials will need to test whether modifying the choice of chemotherapy or adding immunotherapy could improve the chance of organ preservation,” said senior investigator Barbara A. Burtness, MD, an Anthony N. Brady professor of medicine and Chief Translational Research Officer at Yale Cancer Center, chair of the ECOG-ACRIN Head and Neck Committee, and chair of the ECOG-ACRIN Task Force on Advancement for Women.

Cindi Bigelow, CEO of Fairfield-based Bigelow Tea, donates $100,000 to research into toxic side effects of immunotherapy, such as those that cause an interruption in her father David's treatment.

Dr. Pamela Kunz discusses "Advances in the Care of Neuroendocrine Tumors (NETs)."

Investigators from Yale Cancer Center were recently awarded a research grant from the American Cancer Society (ACS) and Yosemite, an oncology focused venture capital firm.

A retrospective cohort study by Yale Cancer Center researchers of nearly 200 patients with melanoma who died after receiving treatment with immunotherapy highlights a need to improve outcomes for patients who progress or relapse after the treatment.

Dr. Rachel Greenup on Yale Cancer Answers.

On August 1st, 2025, Dr. Faye Rogers hosted the Biomedical Summer Undergraduate Research Fellowship Symposium.

The Cellular Therapies Program at Smilow Cancer Hospital is led by Stuart Seropian, MD, Professor of Medicine (Hematology), Iris Isufi , MD, Associate Professor of Medicine (Hematology), and Michael Hurwitz, MD, PhD, Associate Professor of Medicine (Medical Oncology).